Certolizumab pegol in rheumatoid arthritis: current update

Bibliography

• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
   PubMed Web of Science ®Google Scholar
• Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(4 Suppl 73):S72-84
   PubMed Web of Science ®Google Scholar
• Alsalameh S, Winter K, Al-Ward R, et al. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999;49(3):278-85
   PubMed Web of Science ®Google Scholar
• Bluml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int Immunol 2012;24(5):275-81
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol 2012;8(4):235-43
   PubMed Web of Science ®Google Scholar
• Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;(4):CD007848
   Google Scholar
• Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol 2011;40(1):1-7
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492-509
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9(3):164-72
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117(2):244-79
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13(11):1323-32
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Abreu MT. 960 certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology 2009;136:146
   Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348(1-2):36-41
   PubMed Web of Science ®Google Scholar
• EMEA/H/C/001037. Cimzia: european Public Assessment Report, Summary of Product Characteristics. London, UK: European Medicines Agency. 2010. Updated on January 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf [Last accessed 12 January 2014]
   Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68(6):805-11
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 2012;51(12):2204-14
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58(11):3319-29
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68(6):797-804
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Keystone EC, Curtis JR, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 2012;39(7):1326-33
   PubMed Web of Science ®Google Scholar
• Emery P, Furst DE, Keystone EC, et al. Certolizumab pegol remains equally efficacious in the treatment of rheumatoid arthritis over a range of background methotrexate regimens (10-30 mg/wk): analysis of the RAPID 1 trial. Ann Rheum Dis 2010;67(Suppl 1):180
   Google Scholar
• Keystone E, Landewe R, van Vollenhoven R, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• Smolen JS, van Vollenhoven R, Kavanaugh A, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from a 24-week randomized controlled trial and open-label extension study. Arthritis Rheum 2013;65:S988-S89
   Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65(6):753-9
   PubMed Web of Science ®Google Scholar
• Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29(2):238-47
   PubMed Web of Science ®Google Scholar
• Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 2012;51(7):1226-34
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Smolen JS, Emery P, Ferraccioli GF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2014. [Epub ahead of print]
   Google Scholar
• Furst D, Shaikh SA, Greenwald MW, et al. Certolizumab pegol plus methotrexate is similarly effective in active rheumatoid arthritis secondary non-responders to anti-TNF inhibitors: post-hoc analysis of a phase IIIb trial. Arthritis Rheum 2012;64(10):S567-S67
   Web of Science ®Google Scholar
• Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod Rheumatol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology 2012;51(9):1628-38
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Jacobsson L, Schaufelberger C, et al. Magnetic resonance imaging-assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase IIIb study applying magnetic resonance imaging at week 0, 1, 2, 4, 8 and 16. Arthritis Rheum 2013;65:S842-S42
   Web of Science ®Google Scholar
• Strand V, Smolen JS, van Vollenhoven RF, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70(6):996-1002
   PubMed Web of Science ®Google Scholar
• Pope J, Fleischmann R, Dougados M, et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient-reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the REALISTIC 12-week phase IIIb randomised controlled study. Rheumatology 2012;51:135-6
   Web of Science ®Google Scholar
• Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794
   PubMed Web of Science ®Google Scholar
• Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009;58(8):1033-9
   PubMed Web of Science ®Google Scholar
• Lamour S, Bracher M, Nesbitt A. PEG component of certolizumab pegol inhibits stimulated mast cell degranulation. Falk Symp 2009;15(12):S28-8
   Google Scholar
• Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2012;12(2):235-49
   PubMed Web of Science ®Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the british society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology 2011;50(1):124-31
   PubMed Web of Science ®Google Scholar
• Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52(11):3403-12
   PubMed Web of Science ®Google Scholar
• Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann Rheum Dis 2006;65(12):1578-84
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308(9):898-908
   PubMed Web of Science ®Google Scholar
• Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68(5):648-53
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Wolf DC, Forger F, et al. Retrospective analysis of certolizumab pegol use during pregnancy: update of impact on birth outcomes. Arthritis Rheum 2013;65:S187-S88
   Web of Science ®Google Scholar
• Bartelds GM, Wolbink GJ, Stapel S, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006;65(9):1249-50
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54(3):711-15
   PubMed Web of Science ®Google Scholar
• Thomas S, Borazan N, Duan LW, et al. Comparative immunogenicity of tumor necrosis factor inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 2013;65:S866-S66
   Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - results from a large UK national cohort study. Arthritis Rheum 2007;56(1):13-20
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Brown D, et al. Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann Rheum Dis 2007;66:296-6
   Web of Science ®Google Scholar
• Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49(11):2217-19
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Bounthavong M, Mendes MA, et al. Cost utility of tumour necrosis factor-alpha inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a markov model. Pharmacoeconomics 2012;30(7):575-93
   PubMed Web of Science ®Google Scholar
• Purcaru O, Taylor PC, Emery P, Palmer S. PMS42 cost-effectiveness of certolizumab pegol plus methotrexate or as monotherapy for the treatment of active rheumatoid arthritis in the united kingdom. Value Health 2010;13(7):A310-A10
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P, et al. Long-term benefits over more than 4 years of certolizumab pegol combination therapy on workplace and household productivity, and participation in social activities in rheumatoid arthritis: results from the open-label extension study of RAPID1. Value Health 2013;16(7):A570-A70
   Web of Science ®Google Scholar